@article{oai:repo.qst.go.jp:00055351,
 author = {柳, 剛 and 辻, 比呂志 and 溝江, 純悦 and 石川, 仁 and 長谷川, 安都佐 and 高木, 亮 and 若月, 優 and 中野, 隆史 and 大西, 克尚 and その他 and 柳 剛 and 辻 比呂志 and 溝江 純悦 and 石川 仁 and 長谷川 安都佐 and 高木 亮 and 若月 優 and 中野 隆史 and 大西 克尚},
 journal = {HIMAC10年の歩み : HIMAC10周年記念研究成果要覧},
 month = {Jul},
 note = {The phase I/II clinical study of carbon ion radiotherapy (CIRT) for choroidal melanoma was commenced in Jan. 2001 at the National Institute of Radiological Sciences(NIRS), which was based on the long line of the study of proton radotherapy(PRT) since Oct. 1986. PRT is applied to small to medium sized tumor, and carbon is used to large sized tumor at present.
So far 41 patients received PRT. Skin reactions and visual acuity status after the therapy were acceptable. Seven patients developed glaucoma and une of them received enucleation. Local recurrence was observed in one patient and 5-year local control rate was 97.4%. Five-year survival and eye retention rate were 85.4% and 95%, respectively.
On the other hand, thirty-three patients received CIRT and 24 patients with follow-up period of more than 6 months were analyzed. Skin reactions after CIRT were comparable to those of PRT. Neovascular glaucoma was observed in 7 patients and the incidence of glaucoma was strongly depending on the site and size of the tumor.All patients were alive without any local recurrence,and only one patient developed liver metastasis at 22.3 months after the treatment.},
 pages = {68--70},
 title = {脈絡膜悪性黒色腫−陽子線を含めて−},
 year = {2004}
}